SCHEMBL14726401

SCHEMBL14726401

CC(N)c1cccc(C(C)(C)C)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
PDE2A O00408 1/20 0.41
ACHE P22303 3/20 0.41
KIF11 P52732 3/20 0.40
HTR2A P28223 2/20 0.38
HTR2B P41595 2/20 0.38
HTR2C P28335 1/20 0.38
ALDH1A1 P00352 2/20 0.37
NPC1 O15118 1/20 0.37
PLA2G1B P04054 1/20 0.37
NFKB1 P19838 1/20 0.37
CASP3 P42574 1/20 0.37
RAB9A P51151 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
SENP6 Q9GZR1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18793694 1.00 HDAC4 (0.41) HDAC4HDAC2HDAC8PDE2AACHE
SCHEMBL14120875 1.00 HDAC4 (0.41) HDAC4HDAC2HDAC8PDE2AACHE
Hydrochloric Acid SCHEMBL14120967 0.98 HDAC4 (0.40) HDAC4HDAC2HDAC8PDE2AACHE
SCHEMBL15597549 0.86 HTR2A (0.41) PDE2AKIF11HTR2AHTR2BHTR2C
SCHEMBL10431042 0.85 HDAC4 (0.42) HDAC4HDAC2HDAC8ACHEKIF11
SCHEMBL23520737 0.84 PDE2A (0.39) PDE2AKIF11HTR2AHTR2BHTR2C
SCHEMBL18266126 0.84 PDE2A (0.47) PDE2AKIF11HTR2AHTR2BHTR2C
SCHEMBL29755328 0.84 PDE2A (0.47) PDE2AKIF11HTR2AHTR2BHTR2C
SCHEMBL18266127 0.84 PDE2A (0.47) PDE2AKIF11HTR2AHTR2BHTR2C
SCHEMBL27797566 0.84 KIF11 (0.44) KIF11ALDH1A1TACR1IDO1TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014001075-A1 PROCESS FOR RACEMIZING OPTICALLY ACTIVE ARYLALKYLAMINES BASF SE (DE) 2014-01-03 WO claimed
WO-2014001075-A1 PROCESS FOR RACEMIZING OPTICALLY ACTIVE ARYLALKYLAMINES BASF SE (DE) 2014-01-03 WO disclosed
US-20130053382-A1 Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) PALIWAL SUNIL (US) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053382-A1 Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) PDK1, PDPK1, PDK3 HDAC4 495/4885HDAC2 488/4885HDAC8 601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.